Streamlining Dermatology Prior Authorizations with Cognizant TriZetto

For dermatology practices, managing prior authorizations for high-cost biologics and specialized procedures through a clearinghouse like Cognizant TriZetto presents unique operational challenges. Klivira's platform is engineered to streamline this critical workflow.

Revenue cycle directors and prior authorization coordinators in dermatology face a demanding landscape, marked by frequent re-authorizations for chronic conditions and intricate payer policies for specialty drugs and procedures. The efficiency of submitting these requests through clearinghouses like Cognizant TriZetto directly impacts patient access and financial health. Optimizing the flow of clinical data from your EMR to the payer via TriZetto is paramount to avoiding delays and denials.

Navigating Dermatology Prior Authorization Challenges with Cognizant TriZetto

Dermatology prior authorizations frequently involve high-cost biologics for conditions such as psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi), atopic dermatitis, and hidradenitis suppurativa. Additionally, procedures like Mohs micrographic surgery, especially for non-melanoma skin cancers in cosmetically sensitive areas, often trigger PA requirements. Submitting these complex requests accurately through a clearinghouse like Cognizant TriZetto demands precise clinical documentation and adherence to evolving payer rules.

Key Dermatology PA Triggers and Cognizant TriZetto Submission

Biologics for psoriasis and psoriatic arthritis: TNF inhibitors (adalimumab, etanercept), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), and oral targeted therapies.
Biologics for atopic dermatitis: dupilumab, tralokinumab, and oral JAK inhibitors.
Biologics for hidradenitis suppurativa: adalimumab, secukinumab.
Mohs micrographic surgery: High volume for non-melanoma skin cancers, with payer policies varying on indications.
Advanced skin cancer treatments: Immunotherapy for advanced melanoma (pembrolizumab, nivolumab) and targeted therapies.
Phototherapy: PA-relevant when self-administered home phototherapy is prescribed.

EMR Integration and Data Exchange via Cognizant TriZetto for Dermatology

Effective prior authorization workflows in dermatology depend on seamless integration between your EMR and the clearinghouse. Patient demographics, clinical notes, and treatment histories must flow accurately to populate X12 278 transactions submitted through Cognizant TriZetto. Klivira's platform provides the necessary EMR connectivity, often leveraging SMART on FHIR capabilities, to extract relevant clinical data for biologic step therapy documentation, Mohs AUC validation, and other specialty-specific requirements, ensuring data integrity before submission to TriZetto.

Critical Documentation for Dermatology PA Success

For psoriasis/PsA biologics: Diagnosis with PASI/BSA documentation, prior topical/phototherapy trials, conventional systemic therapy trials (e.g., methotrexate), and pre-biologic TB/hepatitis screening per AAD Clinical Guidelines.
For atopic dermatitis biologics: Diagnosis criteria, EASI/SCORAD severity documentation, and topical therapy trials.
For Mohs surgery: Documentation of site (cosmetically/functionally sensitive area), tumor type, and conformance to AAD Appropriate Use Criteria.
Periodic re-authorization for chronic biologic treatment, typically on 6 or 12-month cycles.
Distinction between self-injection at home versus clinic infusion, affecting medical vs. pharmacy benefit routing.

Mitigating Common Dermatology PA Denials with Optimized TriZetto Workflows

Common dermatology PA denials, such as step therapy failures for psoriasis biologics, biosimilar substitution issues, Mohs AUC mismatches, and insufficient disease severity documentation (missing PASI, EASI, BSA scores), can be significantly reduced with a proactive approach. Klivira's automation platform validates these critical data points against payer policies and AAD guidelines *before* the request is transmitted through Cognizant TriZetto, flagging potential issues that could lead to denials and ensuring complete, accurate submissions.

Klivira's Intelligent Automation for Dermatology Prior Authorizations and TriZetto

Klivira's platform is specifically designed to address the complexities of dermatology prior authorizations, integrating directly with your EMR and optimizing submissions through clearinghouses like Cognizant TriZetto. Our solution incorporates AAD-guideline-aware step-therapy logic, AUC validation for Mohs surgery, and robust workflows for periodic re-authorization of chronic biologic treatments. By automating data extraction, policy application, and submission preparation, Klivira reduces manual effort, accelerates turnaround times, and minimizes denial rates for dermatology practices leveraging Cognizant TriZetto.

Frequently asked questions

How does Klivira handle specific dermatology biologic PA requirements when submitting through Cognizant TriZetto?

Klivira automates the validation of clinical criteria for biologics, such as documented trials of prior topical or systemic therapies and required screenings (e.g., TB, hepatitis). Our system ensures these data points are correctly extracted from the EMR and formatted for submission via Cognizant TriZetto, aligning with payer medical policies and AAD Clinical Guidelines.

Can Klivira help with Mohs surgery prior authorizations submitted via Cognizant TriZetto?

Yes, Klivira incorporates logic for Mohs micrographic surgery, validating the tumor type, location, and previous treatments against AAD Appropriate Use Criteria. This ensures that the documentation for Mohs surgery PAs is comprehensive and compliant before being sent through Cognizant TriZetto, reducing the likelihood of denials related to medical necessity.

How does Klivira manage re-authorizations for chronic dermatology conditions through a clearinghouse like TriZetto?

Klivira proactively tracks re-authorization cycles for chronic biologic treatments common in dermatology. Our platform automates the initiation of re-authorization requests, pulls updated clinical documentation (e.g., recent PASI/BSA scores), and prepares the submission for efficient processing through Cognizant TriZetto, ensuring continuity of care without administrative burden.

What EMR data points are critical for dermatology PAs submitted to Cognizant TriZetto?

Critical EMR data points include diagnosis codes, disease severity scores (PASI, EASI, BSA), documentation of failed prior therapies (topicals, phototherapy, systemic agents), screening results (TB, hepatitis), and detailed procedure notes for Mohs surgery. Klivira's integration ensures these are accurately captured and mapped for X12 278 transactions via Cognizant TriZetto.

Does Klivira integrate directly with Cognizant TriZetto's payer platform capabilities?

Klivira optimizes the prior authorization workflow by preparing and submitting compliant requests through clearinghouses like Cognizant TriZetto. While TriZetto acts as a conduit to various payers, Klivira focuses on ensuring the *content* of the PA request is complete and accurate, leveraging EMR data and payer policy intelligence for seamless electronic submission (ePA) wherever supported.